Loading clinical trials...
Loading clinical trials...
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Conditions
Interventions
AXR-159
Vehicle
Locations
3
United States
Andover Eye Associates
Andover, Massachusetts, United States
Andover Eye Associates
Raynham, Massachusetts, United States
Total Eye Care, P.A.
Memphis, Tennessee, United States
Start Date
June 26, 2018
Primary Completion Date
December 28, 2018
Completion Date
January 9, 2019
Last Updated
October 13, 2023
NCT07463950
NCT07363824
NCT07396441
NCT05865379
NCT07298811
NCT07295691
Lead Sponsor
AxeroVision, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions